Calyxt (NASDAQ:CLXT) CEO Michael Carr explains to Proactive how the plant-based synthetic biotechnology company's proprietary Plant Cell Matrix (PCM) sets it apart from its competitors by using a multi-cellular approach.
Carr told Proactive that the company is targeting two to four development deals with its customers this year. It also aim to partner with an infrastructure partner - a third-party organization to provide commercial scaling of its production - by year-end.